Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
-
Published:2023-06-19
Issue:1
Volume:13
Page:
-
ISSN:2044-5385
-
Container-title:Blood Cancer Journal
-
language:en
-
Short-container-title:Blood Cancer J.
Author:
Hilberink Jacobien R.ORCID, van Zeventer Isabelle A., Chitu Dana A., Pabst ThomasORCID, Klein Saskia K.ORCID, Stussi GeorgORCID, Griskevicius Laimonas, Valk Peter J. M.ORCID, Cloos Jacqueline, van de Loosdrecht Arjan A., Breems Dimitri, van Lammeren-Venema Danielle, Boersma Rinske, Jongen-Lavrencic Mojca, Fehr Martin, Hoogendoorn Mels, Manz Markus G.ORCID, Söhne Maaike, van Marwijk Kooy Rien, Deeren Dries, van der Poel Marjolein W. M., Legdeur Marie Cecile, Tick Lidwine, Chalandon Yves, Ammatuna Emanuele, Blum SabineORCID, Löwenberg BobORCID, Ossenkoppele Gert J., Chitu D. A., Klein S. K., Griskevicius L., Valk P. J. M., Cloos J., van de Loosdrecht A. A., Breems D., van Lammeren-Venema D., Boersma R., Jongen-Lavrencic M., Söhne M., van Marwijk Kooy R., Deeren D., van der Poel M. W. M., Legdeur M. C., Tick L., Ammatuna E., Löwenberg B., Ossenkoppele G. J., Huls G., Pabst T., Stussi G., Fehr M., Manz M. G., Chalandon Y., Blum S., Huls Gerwin, ,
Abstract
AbstractTreatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Reference46 articles.
1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52. 2. Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood 2015;125:767–74. 3. Huls G. Azacitidine in AML: A treatment option? Blood 2015;126:283–4. 4. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. 5. Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32:2541–52.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|